Bleomycin Safety and Contraindications

Relative Contraindications

Age‑Related Risk

• Patients older than 40 years have a two‑fold increased risk of bleomycin‑induced pulmonary toxicity; safer alternatives should be used when available. 1
• Patients older than 30 years show an ≈ 5 % higher incidence of grade ≥ 1 pulmonary toxicity compared with younger patients. 2
• A baseline thoracic CT is required for all patients > 40 years before initiating bleomycin therapy. 3

Renal Impairment

• Bleomycin is ≈ 70 % renally excreted; reduced renal function prolongs its half‑life and raises toxicity risk. Renal function must be assessed before each cycle. 4, 3
• Concomitant cisplatin further compromises renal function and promotes bleomycin accumulation. 4

Pre‑Existing Pulmonary Disease

• Pulmonary fibrosis or symptomatic lung disease constitutes a major contraindication to bleomycin; use only after a specialist risk‑benefit assessment. 3, 5
• Hypoxic patients are generally avoided; 66 % of UK specialists would never prescribe bleomycin in this population. 2, 6

Smoking History

• A significant smoking history increases the risk of bleomycin pulmonary toxicity, although precise pack‑year thresholds are not defined. 3
• 77 % of specialists would consider bleomycin in smokers only after an individualized risk assessment. 2, 6

Cumulative Dose Limits

• Patients receiving cumulative bleomycin doses > 300 units must undergo a post‑treatment thoracic CT scan. 3

Monitoring Requirements

Baseline Assessment

• Perform a baseline thoracic CT for all patients > 40 years; obtain baseline pulmonary function tests (PFTs) for reference but do not rely on them alone to predict toxicity. 3, 5
• Renal function assessment is mandatory before therapy initiation. 3

During Treatment Surveillance

• Use a toxicity checklist before and after every cycle, with new cough being the most sensitive early symptom of pulmonary toxicity. 3
• If new cough or dyspnea develops, omit the bleomycin dose immediately and obtain a high‑resolution CT before any further administration. 3
• Chest X‑ray has very low sensitivity for bleomycin toxicity and should never be used for investigation. 5

High‑Risk Patient Management

• Patients with multiple risk factors (age > 40, GFR < 80 ml/min, smoking history, pre‑existing lung disease) should be considered for alternative regimens such as etoposide‑cisplatin (EP) or carboplatin‑etoposide. 1
• Continuation of bleomycin when new respiratory symptoms arise requires consultant‑level decision‑making with multidisciplinary input, including experienced radiologists. 3, 5

Common Pitfalls

• Do not rely solely on PFTs to decide whether to start bleomycin; they correlate weakly with toxicity and only at treatment end. 3, 5
• Do not use chest X‑ray to evaluate suspected bleomycin toxicity; high‑resolution CT is the investigation of choice. 5
• Do not continue bleomycin without consultant approval when new respiratory symptoms develop; cessation can reverse lung injury. 3, 5
• Bleomycin toxicity is not purely dose‑dependent; idiosyncratic severe reactions can occur at lower cumulative doses. 4
• Always consider infection as a potential mimic or co‑existing condition with bleomycin‑related pulmonary toxicity. 3

Contraindications to Bleomycin for Germ Cell Tumours

Relative Contraindications Requiring Heightened Caution

• The British Journal of Cancer recommends that extreme caution is required in patients with advanced age (>40 years), impaired renal function (GFR <80 ml/min), significant smoking history, and pre-existing lung disease, particularly pulmonary fibrosis 7
• Pre-existing lung disease, particularly pulmonary fibrosis or other symptomatic pulmonary pathology, represents a major risk factor for bleomycin pulmonary toxicity, according to the British Journal of Cancer 7, 8
• Significant smoking history is identified as a risk factor requiring caution for bleomycin use, though specific pack-year thresholds are not definitively established, as reported by the British Journal of Cancer 7
• Baseline CT thorax is recommended for all patients over age 40, and baseline pulmonary function tests should be considered as a reference point, according to the British Journal of Cancer 8
• A toxicity checklist should be used before and after every cycle, with particular attention to new cough, and renal function should be checked prior to every cycle, as recommended by the British Journal of Cancer 8
• If new cough or dyspnea develops, HRCT should be obtained immediately, and bleomycin dose should be omitted until HRCT evaluation is complete, according to the British Journal of Cancer 7, 9
• The British Journal of Cancer advises against using pulmonary function tests in isolation to decide whether to treat with bleomycin, as they are only weakly correlated with toxicity risk 8
• The British Journal of Cancer recommends against relying on chest X-ray for toxicity detection, as it has extremely low sensitivity, and HRCT is the investigation of choice 7
• The British Journal of Cancer advises against continuing bleomycin in the face of new respiratory symptoms without consultant-level decision-making and HRCT evaluation 7, 9

Bleomycin Pulmonary Toxicity: Risk Assessment, Monitoring, and Management

Risk Factors

• Age > 40 years confers an approximately 2‑fold increased risk of bleomycin‑induced pulmonary toxicity. 10
• A pre‑existing lung disease (e.g., pulmonary fibrosis or symptomatic interstitial pathology) is a major contraindication to bleomycin therapy. 11
• Significant smoking history further elevates the risk of pulmonary toxicity, although precise exposure thresholds are not defined. 12
• Reduced renal function (estimated GFR < 80 mL/min) increases the risk of toxicity by roughly 3.3‑fold, reflecting the drug’s ~70 % renal excretion. 13

Baseline Assessment

• All patients > 40 years should undergo a baseline thoracic CT scan before initiating bleomycin. 10
• Baseline pulmonary function tests (PFTs) may be recorded for reference but must not be used in isolation to predict toxicity or to decide on treatment initiation. [10][12]
• Renal function must be evaluated prior to the first dose of bleomycin. 13

Ongoing Surveillance During Treatment

• A standardized toxicity checklist should be completed before and after every bleomycin cycle. [10][13]
• Renal function should be reassessed prior to each treatment cycle because declining renal function heightens toxicity risk. 13
• Cough is the most sensitive clinical symptom for early detection of pulmonary toxicity; any new cough should prompt immediate investigation. [10][13]

Diagnostic Evaluation of Suspected Toxicity

• If a patient develops new cough or dyspnea, an immediate high‑resolution CT (HRCT) should be performed and the scheduled bleomycin dose omitted pending evaluation. [11][12]
• HRCT is the investigation of choice for suspected bleomycin‑related lung injury; chest X‑ray has extremely low sensitivity and should not be used for this purpose. 11
• Pulmonary function testing is not a first‑line diagnostic tool; when used, diffusion capacity for carbon monoxide (DLCO) provides the most informative parameter. [10][12]

Management of Confirmed Toxicity

• Immediate discontinuation of bleomycin is recommended once pulmonary toxicity is suspected or confirmed, as cessation may reverse lung damage while continuation can worsen injury. [10][11]
• For HRCT‑confirmed toxicity, oral prednisolone at 0.5 mg/kg daily for 7 days followed by a taper is advised. [10][13]
• A low threshold for empirical antimicrobial therapy should be maintained because infection can mimic or coexist with bleomycin‑related toxicity. [10][13]
• Consultation with a respiratory physician experienced in interstitial lung disease is recommended for all confirmed cases. [10][13]

Post‑Treatment Follow‑up

• Patients who have received a cumulative bleomycin dose > 300 units must undergo a post‑treatment thoracic CT scan to assess for late pulmonary changes. [10][13]
• Follow‑up investigations should be driven by the presence of respiratory symptoms rather than routine imaging alone. 13
• All treated patients should receive an advice sheet outlining potential pulmonary complications and guidance on when to seek medical attention. [10][13]

Critical Pitfalls (What to Avoid)

• Do not rely solely on baseline or serial PFT results to decide on initiating or continuing bleomycin, as the correlation with toxicity is weak. 12
• Do not use chest X‑ray as the primary imaging modality for suspected toxicity; HRCT is mandatory. 11
• Do not continue bleomycin in the presence of new respiratory symptoms without senior consultant approval and multidisciplinary input. 11

All statements are derived from peer‑reviewed evidence cited in the British Journal of Cancer (2018). No explicit strength of evidence grading was provided in the source material.